Skip to main content
. Author manuscript; available in PMC: 2017 Mar 14.
Published in final edited form as: Vaccine. 2016 Feb 10;34(12):1452–1458. doi: 10.1016/j.vaccine.2016.01.064

Figure 1.

Figure 1

Figure 1

Serum norovirus-specific IgG and IgA production following intranasal immunization with GelVac™ vaccine powders. Female Hartley guinea pigs were immunized intranasally with 20mg of powder formulation containing various amounts of GI or GII VLP on days 0 and 21. Serum samples were collected on days 0, 14, 21, 42, and 56 and analyzed for specific IgG antibodies GI (A) and GII.4 (B) Norovirus. Day 56 samples were analyzed in pooled samples for specific IgA antibodies against GI (C) and GII.4 (D) Norovirus. Error bars are provided as geometric standard error. *P<0.05 as compared to the placebo control group. Exact adjusted p-values following Dunnett’s multiple comparison test following two-way ANOVA is shown in Supplementary Table 2sA–B.